Cover Image
Market Research Report

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A - Pipeline Review, H1 2019

Published by Global Markets Direct Product code 408758
Published Content info 67 Pages
Delivery time: 1-2 business days
Price
Back to Top
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A - Pipeline Review, H1 2019
Published: June 10, 2019 Content info: 67 Pages
Description

Summary:

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) is an enzyme that is encoded by the DYRK1A gene. DYRK1A autophosphorylates on tyrosine serine and threonine residues but phosphorylate substrates only on serine or threonine residues. It plays a significant role in a signaling pathway regulating cell proliferation and involved in brain development.

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) pipeline Target constitutes close to 18 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 8 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders, Metabolic Disorders, Oncology, Immunology and Musculoskeletal Disorders which include indications Alzheimer's Disease, Down Syndrome, Type 1 Diabetes (Juvenile Diabetes), Autoimmune Disorders, Colon Cancer, Dementia, Depression, Glioblastoma Multiforme (GBM), Lung Cancer, Osteoarthritis, Pancreatic Cancer, Parkinson's Disease, Post-Traumatic Stress Disorder (PTSD) and Prostate Cancer.

The latest report Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A - Pipeline Review, H1 2019, outlays comprehensive information on the Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1)
  • The report reviews Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Product Code: GMDHC1873TDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Overview
  • Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Companies Involved in Therapeutics Development
    • Avanti Biosciences Inc
    • Carna Biosciences Inc
    • Felicitex Therapeutics Inc
    • ManRos Therapeutics
    • NeuroNascent Inc
    • Pharmasum Therapeutics AS
    • Samumed LLC
    • San Biotechnology Co Ltd
  • Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Drug Profiles
    • ABI-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ABI-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adavivint - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FX-9847 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KPO-1143 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NNI-351 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PST-1100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PST-900 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SM-07883 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Activate DYRK1A for Type 1 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit DYRK1A for Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit DYRK1A for Alzheimer's Disease and Down Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit DYRK1A for Down Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit DYRK1A for Parkinson's Disease and Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Dyrk1a for Alzheimer's Disease and Down syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit DYRK1A for Alzheimer's Disease and Down Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit DYRK1A for Autoimmune Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit DYRK1A for Glioblastoma Multiforme - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Dormant Products
  • Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Discontinued Products
  • Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Product Development Milestones
    • Featured News & Press Releases
      • May 02, 2019: Samumed launches phase 3 Lorecivivint (SM04690) Clinical Program in Knee Osteoarthritis
      • Apr 10, 2019: Samumed announces multiple presentations at the 19th World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
      • Apr 04, 2019: Samumed doses first subject in phase 1 trial of SM07883, a potential treatment for Alzheimer's Disease
      • Mar 07, 2019: Samumed to present clinical data on SM04690 at the American Academy of Orthopaedic Surgeons 2019 Annual Meeting
      • Feb 28, 2019: Samumed announces Positive End-of-Phase 2 Meeting with FDA for SM04690 in knee osteoarthritis
      • Jan 29, 2019: Samumed to present novel biological targets of SM04690 for treatment of knee osteoarthritis
      • Nov 05, 2018: Samumed announces multiple presentations at 6th world congress on controversies, debates & consensus in bone, muscle & joint diseases.
      • Oct 24, 2018: Samumed phase 2b trial in knee osteoarthritis meets primary endpoints
      • Oct 18, 2018: Samumed to Present Preclinical Data on SM07883 at the 11th Clinical Trials on Alzheimer's Disease (CTAD) Congress
      • Oct 16, 2018: Samumed to present data from phase 2b trial of SM04690 for treatment of knee osteoarthritis at 2018 American College of Rheumatology (ACR) Annual Meeting
      • Jul 27, 2018: Samumed Presents Positive Preclinical Data on SM07883 at 2018 Alzheimer's Association International Conference
      • Jul 17, 2018: Samumed to Present Preclinical Data on SM07883, a Potential First-in-Class Alzheimer's Disease Candidate, at the Alzheimer's Association International Conference 2018
      • Jun 29, 2018: Samumed Announces Presentation of Clinical Data Analysis on SM04690 for Treatment of Knee Osteoarthritis at International Workshop on Osteoarthritis Imaging (IWOAI) 2018 Conference
      • Jun 20, 2018: Samumed Presents Clinical and Preclinical Data at European League Against Rheumatism (EULAR) 2018 Annual Congress
      • Jun 08, 2018: Samumed Announces Presentations on SM04690 at the European League Against Rheumatism (EULAR) 2018 Annual Congress
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2019
  • Number of Products under Development by Therapy Areas, H1 2019
  • Number of Products under Development by Indication, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Number of Products under Investigation by Universities/Institutes, H1 2019
  • Products under Investigation by Universities/Institutes, H1 2019
  • Number of Products by Stage and Mechanism of Actions, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Pipeline by Avanti Biosciences Inc, H1 2019
  • Pipeline by Carna Biosciences Inc, H1 2019
  • Pipeline by Felicitex Therapeutics Inc, H1 2019
  • Pipeline by ManRos Therapeutics, H1 2019
  • Pipeline by NeuroNascent Inc, H1 2019
  • Pipeline by Pharmasum Therapeutics AS, H1 2019
  • Pipeline by Samumed LLC, H1 2019
  • Pipeline by San Biotechnology Co Ltd, H1 2019
  • Dormant Projects, H1 2019
  • Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development by Stage of Development, H1 2019
  • Number of Products under Development by Therapy Areas, H1 2019
  • Number of Products under Development by Top 10 Indications, H1 2019
  • Number of Products by Mechanism of Actions, H1 2019
  • Number of Products by Stage and Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
Back to Top